$SI earnings report

Shoulder Innovations reports Q3 2026 net revenue of $16,191 thousand, up 38%, and raises FY2026 net revenue guidance to $68 million to $70 million. AlphAI read Shoulder Innovations's Q3 FY2026 filing as solid. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readSI · Q3 2026 · ended 2026-09-30

Shoulder Innovations reports Q3 2026 net revenue of $16,191 thousand, up 38%, and raises FY2026 net revenue guidance to $68 million to $70 million

✓Solid quarter

Net revenue rose 38% in the quarter and 52% year to date, gross margin rose to 78.5% from 76.2%, and adjusted EBITDA loss narrowed. Operating loss was flat at $(7,597) thousand because operating expenses grew faster than gross profit, and the company does not report gross margin, operating expense or tax guidance.

Revenue
$16.2M
38% y/y
Gross margin · GAAP
78.5%
EPS · GAAP
$(0.34)
FY2026 (full year 2026 net revenue) outlook
$68 million to $70 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net revenue, Q3 2026 (three months ended September 30, 2026)GAAP$16.19M–38%
Cost of goods sold, Q3 2026GAAP$3.49M––
Gross profit, Q3 2026GAAP$12.71M––
Gross margin, Q3 2026GAAP78.5%––
Selling, general and administrative expenses, Q3 2026GAAP$17.14M–14%
Research and development expenses, Q3 2026GAAP$3.17M–107%
Operating loss, Q3 2026GAAP−$7.60M––
Interest (income) expense, net, Q3 2026GAAP−$574K––
Net loss, Q3 2026GAAP−$7.05M––
Net loss per share, basic and diluted, Q3 2026GAAP$(0.34)––
Adjusted EBITDA, Q3 2026non-GAAP−$5.49M––
Implant systems sold, Q3 2026other2,126 total implant systems–approximately 34% increase
Average selling price of implant systems, Q3 2026other$7,616–2% increase
Net revenue, nine months ended September 30, 2026GAAP$50.07M–52% year-to-date revenue growth (as stated in headline)
Cost of goods sold, nine months ended September 30, 2026GAAP$10.94M––
Gross profit, nine months ended September 30, 2026GAAP$39.13M––
Selling, general and administrative expenses, nine months ended September 30, 2026GAAP$55.43M––
Research and development expenses, nine months ended September 30, 2026GAAP$10.31M––
Operating loss, nine months ended September 30, 2026GAAP−$26.61M––
Net loss, nine months ended September 30, 2026GAAP−$25.58M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$(1.23)––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP−$20.47M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

FY2026 (full year 2026 net revenue) outlook

  • Revenue$68 million to $70 million
  • NoteGrowth of approximately 44% to 48% over full year 2025 net revenue
  • NotePrior guidance printed in this filing: $67 million to $69 million, representing growth of approximately 42% to 46% over full year 2025 net revenue
  • NoteThe filing states: Increased full year 2026 net revenue guidance to $68 million to $70 million

Capital returns

  • No share repurchases or dividends are reported in the filing.

What drove it

  • The company states that the Q3 revenue increase was primarily due to more implant systems sold, driven by new surgeon customers and higher utilization among existing customers, as well as a higher average selling price of implant systems.
  • The company states that the gross margin increase was due to higher average selling price of implant systems and benefits from cost reduction programs.
  • The company states that the SG&A increase was primarily due to investments in the commercial organization and higher variable selling expenses, partially offset by lower legal expenses.
  • The company states that the R&D increase was due to investment in new product development efforts, including substantial work related to the InSet Neo robotic platform.
  • The company states that the Q3 net loss decrease was primarily due to changes in the fair value of the company's preferred stock warrant liability and convertible notes in the prior year.
  • The company states that the adjusted EBITDA loss decrease was primarily due to higher gross profit, partially offset by the operating expenses, and that the prior year included changes in the fair value of the preferred stock warrant liability and convertible notes.
  • Recent business highlights include first surgical cases with InSet Go, FDA 510(k) clearance and commercial launch of the N-22 humeral head, a partnership with ALM Ortho, a new Chief Commercial Officer, and a settlement agreement with Catalyst OrthoScience Inc. to resolve patent litigation.

Concerns

  • Q3 operating loss of $(7,597) thousand was essentially unchanged from $(7,641) thousand in Q3 2025, as the company states higher gross profit was offset by increased operating expenses.
  • Q3 SG&A grew 14% and R&D grew 107%, while gross profit rose from $8,961 thousand to $12,705 thousand in the same quarter.
  • Net loss improvement in Q3 is attributed by the company mainly to prior-year fair value changes, not to operating results.
  • Net loss per share of $(0.34) in Q3 2026 compares with $(0.64) in Q3 2025, and the filing shows a higher weighted average share count of 20,844,461 versus 13,604,556.
  • Cash and marketable securities declined from $124,305 thousand at December 31, 2025 (cash $26,871 thousand plus marketable securities $97,434 thousand) to $92.3 million at September 30, 2026, a decline the filing does not explain in cash flow terms.
  • Nine-month operating loss widened to $(26,609) thousand from $(17,797) thousand, as SG&A and R&D expenses rose in the period.

What to watch

  • Delivery against the raised FY2026 net revenue guidance of $68 million to $70 million in the fourth quarter.
  • Trend in SG&A and R&D spending relative to gross profit, given the company's statement that operating expenses offset higher gross profit in Q3.
  • Commercial launch progress of the N-22 humeral head and early adoption of InSet Go.
  • Timing of the planned FDA submission of InSet Neo, the company's shoulder-specific robotic platform.
  • Implant system volume and average selling price trends into 2027, as management referred to building momentum into 2027.
  • Balance sheet liquidity, given cash and marketable securities of $92.3 million at September 30, 2026.

Balance sheet and cash flow

  • Cash and cash equivalents: $36,416 thousand at September 30, 2026, versus $26,871 thousand at December 31, 2025.
  • Marketable securities: $55,918 thousand at September 30, 2026, versus $97,434 thousand at December 31, 2025.
  • Cash and cash equivalents and marketable securities totaled $92.3 million at September 30, 2026, as stated in the release.
  • Total assets: $145,574 thousand at September 30, 2026, versus $169,907 thousand at December 31, 2025.
  • Long-term debt: $14,848 thousand at September 30, 2026, versus $14,911 thousand at December 31, 2025.
  • Total liabilities: $27,148 thousand at September 30, 2026, versus $29,157 thousand at December 31, 2025.
  • Total stockholders' equity: $118,426 thousand at September 30, 2026, versus $140,750 thousand at December 31, 2025.
  • Accounts payable: $4,560 thousand at September 30, 2026, versus $8,874 thousand at December 31, 2025.
  • Inventories, net: $24,380 thousand at September 30, 2026, versus $21,591 thousand at December 31, 2025.
  • Trade accounts receivable, net: $9,286 thousand at September 30, 2026, versus $8,268 thousand at December 31, 2025.
  • Depreciation and amortization expense: $1,117 thousand in Q3 2026 versus $843 thousand in Q3 2025; $3,382 thousand nine months 2026 versus $2,228 thousand nine months 2025.
  • Stock-based compensation expense: $1,018 thousand in Q3 2026 versus $298 thousand in Q3 2025; $2,825 thousand nine months 2026 versus $615 thousand nine months 2025.
  • The filing does not include a cash flow statement, so operating cash flow and free cash flow are not reported.

Analysis

Shoulder Innovations reported third quarter 2026 net revenue of $16,191 thousand, up 38% from $11,756 thousand in the third quarter of 2025. The company attributes the increase mainly to more implant systems sold, driven by new surgeon customers and higher utilization among existing customers, together with a higher average selling price. The release reports 2,126 total implant systems sold, an approximate 34% increase, and an average selling price of $7,616, a 2% increase. Nine-month net revenue was $50,074 thousand against $32,901 thousand, which the headline describes as 52% year-to-date growth.

Gross margin was 78.5% against 76.2% a year earlier. Gross profit rose to $12,705 thousand from $8,961 thousand, and the company attributes the margin gain to a higher average selling price and to cost reduction programs. Operating expenses grew faster than gross profit. SG&A rose 14% to $17,137 thousand, which the company attributes to commercial organization investment and higher variable selling expenses, partly offset by lower legal expenses. R&D more than doubled, rising 107% to $3,165 thousand, which the company links to new product development including work on the InSet Neo robotic platform. As a result, the operating loss was $(7,597) thousand, essentially unchanged from $(7,641) thousand.

Net loss narrowed to $(7,048) thousand from $(8,729) thousand. The company states that the decrease was primarily due to changes in the fair value of the preferred stock warrant liability and convertible notes recorded in the prior year, so the improvement is not described as operating in origin. Adjusted EBITDA, a non-GAAP measure, was $(5,487) thousand against $(7,510) thousand, and the company attributes that narrowing mainly to higher gross profit, partly offset by operating expenses. On a nine-month basis, the operating loss widened to $(26,609) thousand from $(17,797) thousand, while nine-month net loss narrowed to $(25,580) thousand from $(32,587) thousand.

The balance sheet shows cash and cash equivalents of $36,416 thousand and marketable securities of $55,918 thousand at September 30, 2026, totaling $92.3 million as stated in the release. Total assets were $145,574 thousand and stockholders' equity $118,426 thousand. The filing contains no cash flow statement and no capital return activity. Long-term debt was $14,848 thousand.

Full-year 2026 net revenue guidance was raised to $68 million to $70 million, from the prior $67 million to $69 million, which the filing presents as growth of approximately 44% to 48% and previously approximately 42% to 46% over full year 2025 net revenue. The release gives no gross margin, operating expense or tax guidance. The quarter shows strong top-line growth and gross margin expansion, while operating expenses continue to absorb most of the gross profit gain. The R&D increase and the InSet Neo program are the items to track into 2027.

Management, verbatim

“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving,”

Rob Ball, CEO, Shoulder Innovations

“This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”

Rob Ball, CEO, Shoulder Innovations

Not in the filing

stated, not guessed
  • Gross margin, operating expense and tax rate guidance are not provided.
  • Prior-quarter (Q2 2026) figures are not printed, so all qoq_change and prior_quarter fields are null.
  • The year-over-year change in gross margin in basis points is not printed; only the two quarterly percentages are given.
  • The year-over-year change in gross profit, cost of goods sold, operating loss, net loss and adjusted EBITDA is not printed as a percentage.
  • Prior-year implant system units and average selling price figures are not printed, so their prior_year fields are null.
  • The company's cash flow statement is not included, so operating cash flow, investing cash flow, free cash flow and capital expenditures are not reported.
  • Share repurchase and dividend data are not reported.
  • Segment or geographic revenue breakdowns are not reported.
  • Consensus estimates, analyst expectations and share price reaction are not provided in the documents.
  • The 52% year-to-date growth figure appears in the headline only; the filing does not print a separate nine-month percentage change line in the table.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readSI · second quarter 2026 · ended June 30, 2026

Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook

✓Solid quarter

Net revenue grew 56%, gross margin expanded to 78.3%, implant-system volume increased approximately 50%, and the company raised full-year 2026 net revenue guidance. Operating loss widened as the company increased commercial and research and development investment.

Revenue
$17.2M
56% y/y
Gross margin · GAAP
78.3%
full year 2026 outlook
$67 million to $69 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net revenueGAAP$17.2M–56%
First half 2026 revenue growthother60%––
Gross marginGAAP78.3%––
Average selling price of implant systemsother$7,674–5%
Total implant systems soldother2,238–approximately 50%
Selling, general and administrative expensesGAAP$20.1M–56%
Research and development expensesGAAP$3.4M–141%
Operating lossGAAP$10M––
Net lossGAAP$10.2M––
Adjusted EBITDAnon-GAAPloss of $8.0 million––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

full year 2026 outlook

  • Revenue$67 million to $69 million
  • Notegrowth of approximately 42% to 46% over full year 2025 net revenue

What drove it

  • Net revenue growth was due to an increase in the number of implant systems sold and an increase in the number of customers.
  • Gross-margin expansion was due to increases in the average selling price of implant systems and benefits from negotiated cost reduction programs.
  • The company initiated full commercial launch of the N-22 glenosphere for patients with metal hypersensitivity.
  • The company initiated full commercial launch of a new titanium plasma spray (TPS) baseplate line extension for reverse procedures.
  • The company expanded its commercial organization in the second quarter to support increased business scale.

Concerns

  • Selling, general and administrative expenses increased 56% to $20.1 million, primarily reflecting commercial-organization investments, higher variable selling expenses, and increased public-company costs.
  • Research and development expenses increased 141% to $3.4 million due to new product development efforts, including development related to the robotic platform strategic partnership.
  • Operating loss was $10.0 million, compared to a loss of $5.9 million in the second quarter of 2025.

What to watch

  • Execution against full-year 2026 net revenue guidance of $67 million to $69 million.
  • Commercial adoption following the launches of the N-22 glenosphere and TPS baseplate line extension.
  • Implant-system volume, average selling price, and customer growth.
  • The pace of commercial and research and development spending relative to revenue growth and gross-margin performance.
  • Use of the credit facilities and working capital capacity.

Balance sheet and cash flow

  • As of June 30, 2026, cash and cash equivalents, and marketable securities totaled $99.0 million.
  • Closed two new credit facilities for an aggregate amount of up to $50 million with Stifel Venture Banking, refinancing existing debt and adding undrawn working capital capacity.

Analysis

Shoulder Innovations reported a strong top-line quarter, with net revenue increasing 56% to $17.2 million. Management attributed the increase to more implant systems sold and more customers. The company sold 2,238 total implant systems, an approximate 50% increase over the second quarter of 2025, while average selling price increased 5% to $7,674. The release also highlighted first-half 2026 revenue growth of 60%.

Mix and execution supported profitability at the gross-profit level. Gross margin increased to 78.3% from 76.2%, driven by higher average selling prices and negotiated cost reduction programs. The margin improvement occurred alongside commercial expansion and product activity, including full commercial launches of the N-22 glenosphere for patients with metal hypersensitivity and a TPS baseplate line extension for reverse procedures.

Operating spending rose materially as the company invested for scale. Selling, general and administrative expenses increased 56% to $20.1 million, reflecting commercial investments, higher variable selling costs, and public-company costs. Research and development expense increased 141% to $3.4 million, including work related to the robotic platform strategic partnership. These investments contributed to operating loss widening to $10.0 million from a loss of $5.9 million, despite the gross-margin expansion.

Net loss improved to $10.2 million from a net loss of $19.2 million, and adjusted EBITDA loss improved to $8.0 million from a loss of $18.1 million. The company said the prior-year period included a significant charge from changes in the fair value of its preferred stock warrant liability and Series E purchase option. As of June 30, 2026, cash and cash equivalents and marketable securities totaled $99.0 million, and the company closed credit facilities of up to $50 million that refinanced existing debt and added undrawn working capital capacity.

Management raised full-year 2026 net revenue guidance to $67 million to $69 million, representing growth of approximately 42% to 46% over full-year 2025 net revenue. The guide was raised from the $65 million to $68 million range cited in the release, although no prior outlook document was supplied for formal guidance-performance comparison. The central execution items are whether implant volume, customer additions, pricing, and gross margin remain durable while commercial and product-development investment continues.

Management, verbatim

Our second quarter results build on a strong start to the year and reflect remarkable momentum across every dimension of our business. We continued to rapidly onboard new surgeons against a large, underpenetrated market opportunity, deepened utilization within our existing surgeon base, and advanced a broad and increasingly differentiated product pipeline. This performance resulted in net revenue growth of 56% and implant volume growth of approximately 50%, enabling us to increase our outlook for the full year.

Rob Ball, CEO of Shoulder Innovations

Our confidence in what lies ahead has never been stronger. The commercial organization we’ve built continues to perform, our innovation pipeline is growing, and our conviction in the team’s ability to execute is high. With a strengthened financial foundation following our recent debt refinancing, we believe Shoulder Innovations remains in the early stages of what we can accomplish in transforming shoulder surgical care, and we look forward to demonstrating that in the back half of 2026 and beyond.

Rob Ball, CEO of Shoulder Innovations

Not in the filing

stated, not guessed
  • GAAP earnings per share
  • Non-GAAP earnings per share
  • Prior-quarter comparisons for reported metrics
  • Segment revenue disclosure
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Debt outstanding balance
  • Share repurchases
  • Dividends
  • Guidance for gross margin, operating expenses, tax rate, earnings per share, operating cash flow, or free cash flow
  • Previous-release outlook required for vs_prior_guidance comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about SI earnings dates

When is Shoulder Innovations's next earnings date?
AlphAI has no date for SI yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.